#16
|
|||
|
|||
Ñ ìèêðîýëåìåíòàìè ïîðÿäîê
Íà ÝÝÃ îò 26.04 ýïèàêòèâíîñòè íå óâèäåëà |
#17
|
|||
|
|||
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
âîñïîëüçóéòåñü ïåðåâîä÷èêîì |
#18
|
|||
|
|||
Ñïàñèáî çà ññûëêó,ïðî÷èòàëè.×èòàëè â èíòåðíåòå àíàëîãè÷íûå îïèñàíèÿ êîãäà ïîñòàâèëè ýòîò äèàãíîç Àà ïîä âîïðîñ.Êàêèå èññëåäîâàíèÿ åùå ìîæíî ïðîéòè äëÿ èñêëþ÷åíèÿ èëè ïîäòâåðæäåíèÿ ýòîãî äèàãíîçà?
|
#19
|
||||
|
||||
êàê æå âû ÷èòàëè/ïîíÿëè, åñëè çàäàåòå òàêèå âîïðîñû, êîãäà â òåêñòå:
Molecular genetic testing for mutations in the ATP1A3 gene is available on a clinical basis via individual targeted gene sequencing or as part of larger gene panels. Increasingly, ATP1A3 mutations are identified in the context of clinical exome sequencing. 34 different ATP1A3 mutations were detected in 85 % (132/155) patients, 7 of which were novel. In general, mutations were found to cluster into five different regions. The most frequent mutations included: p.Asp801Asn (43 %; 57/132), p.Glu815Lys (16 %; 22/132), and p.Gly947Arg (11 %; 15/132). Of these, p.Glu815Lys was associated with a severe phenotype, with more severe intellectual and motor disability. p.Asp801Asn appeared to confer a milder phenotypic expression, and p.Gly947Arg appeared to correlate with the most favourable prognosis, compared to the other two frequent mutations. Overall, the comparison of the clinical profiles suggested a gradient of severity between the three major mutations with differences in intellectual (p = 0.029) and motor (p = 0.039) disabilities being statistically significant. For patients with epilepsy, age at onset of seizures was earlier for patients with either p.Glu815Lys or p.Gly947Arg mutation, compared to those with p.Asp801Asn mutation (p < 0.001). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#20
|
|||
|
|||
Öèòàòà:
Ìû èìåëëè ââèäó ïîìèìî ýòîãî àíàëèçà ,÷òî åùå ìîæíî ñäàòü ,îí âñå-òàêè ïðèìåðíî 3ìåñ ãîòîâèòñÿ, |
#21
|
|||
|
|||
Äðóãèõ ñïåöèôè÷åñêèõ àíàëèçîâ ÿ íå íàøëà
Ôëóíàðèçèí ó íàñ íå çàðåãèñòðèðîâàí, íî íå çàïðåùåí, ìîæíî ïðîáîâàòü, ÿ äóìàþ, íå äîæèäàÿñü àíàëèçà Îñòàëüíûå âîçìîæíûå ïðè÷èíû óæå èñêëþ÷åíû |
#22
|
|||
|
|||
Öèòàòà:
Êàê ðàñ÷èòàòü äîçèðîâêó ? Ðåáåíêó ãîä è ìåñÿö âåñèò îðèåíòèðîâî÷íî 9800 - 10 êã , åñòü ëè îò íåãî ñîíëèâîñòü? Òîðìîçèò ëè ðàçâèòèå ðåáåíêà? |
|
#23
|
|||
|
|||
|
#24
|
|||
|
|||
Öèòàòà:
âîò ÝÝÃ äåëàëè ïðè ãîñïèòàëèçàöèè |
#25
|
|||
|
|||
ß æå íàïèñàëà, ÷òî â ÐÔ ïðåïàðàò íå çàðåãèñòðèðîâàí
|
#26
|
|||
|
|||
Ïàïêà èç Îáëàêà Mail.Ru
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Äîáðîå óòðî! äîáàâèëè íîâûå ðåçóëüòàòû àíàëèçîâ : cl, ãåðïåñ 6ãî òèïà, ÒÒÃ , ñò3,ñò4, îáùèé àíàëèç êðîâè. |